New pill helps dialysis patients control dangerous phosphorus levels
NCT ID NCT06745531
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new medicine called TS-172 in 101 adults on hemodialysis who had high phosphorus levels. The goal was to see if the drug could help more patients reach a safe phosphorus level in their blood. Results showed that TS-172 was better than a placebo at controlling phosphorus, which is important for managing kidney disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug that boosts red blood cells help anemia in kidney disease?
- Predicting kidney trouble in older adults: a data-driven approach to clearer lab results
- Could delaying kidney implant during heart transplant reduce complications?
- Can a new tablet formulation improve how a kidney disease drug is absorbed?
- New drug aims to reduce kidney damage in chronic disease
- Contrast dye Double-Dose: new study tracks kidney fallout in ICU patients